Stockscreener 앱 받기
150.88
0.03%
-0.05
시간 외 거래:
150.88
전일 마감가:
$150.93
열려 있는:
$151.42
하루 거래량:
1.66M
Relative Volume:
1.05
시가총액:
$287.89B
수익:
$54.66B
순이익/손실:
$13.58B
주가수익비율:
21.50
EPS:
7.0171
순현금흐름:
$16.05B
1주 성능:
+1.86%
1개월 성능:
+1.89%
6개월 성능:
+11.74%
1년 성능:
+29.61%
1일 변동 폭
$150.20
$152.57
1주일 범위
$148.64
$154.71
52주 변동 폭
$112.34
$170.46
노바티스 ADR Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
150.88 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,112.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.20 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
221.23 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.44 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
노바티스 ADR Stock (NVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Argus | Hold → Buy |
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2026-01-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-12-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-09-12 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-08-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Underweight |
| 2025-02-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-12-04 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-09-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-09-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-09-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-19 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-23 | 개시 | BMO Capital Markets | Market Perform |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-09-25 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-03-27 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2023-01-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-12-05 | 업그레이드 | Stifel | Hold → Buy |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-05-09 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 재개 | Citigroup | Buy |
| 2021-12-14 | 다운그레이드 | Redburn | Buy → Neutral |
| 2021-12-06 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 개시 | Bernstein | Mkt Perform |
| 2021-03-10 | 다운그레이드 | Argus | Buy → Hold |
| 2021-02-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2020-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-03-10 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-04-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-04-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2018-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 재확인 | Leerink Partners | Outperform |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 개시 | Liberum | Buy |
모두보기
노바티스 ADR 주식(NVS)의 최신 뉴스
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study - TradingView
Novartis AG Stock (CH0012005267): In focus on a quiet Sunday session - AD HOC NEWS
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) - GlobeNewswire Inc.
Novartis AG stock (CH0012005267): Pluvicto data keep focus on Swiss blue-chip pharma - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts - AD HOC NEWS
Novartis AG stock (CH0012005267): shares little changed as investors digest Swiss pharma group’s s - AD HOC NEWS
Novartis AG stock (CH0012005267): focus on Sandoz spin-off and pipeline momentum - AD HOC NEWS
Novartis AG stock (CH0012005267): eyeing Sandoz spin-off and new drug approvals - AD HOC NEWS
Novartis AG stock (CH0012005267): new MS drug filing and Q1 momentum attract attention - AD HOC NEWS
Novartis AG stock (CH0012005267): Q1 update, Sandoz deconsolidation and pharma focus draw investor a - AD HOC NEWS
Novartis AG stock (CH0012005267): oncology focus, new drug readout and solid 2025 guidance in view - AD HOC NEWS
NVS Stock Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis stock (CH0012005267): FDA progress and market focus - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): dividend profile and pipeline focus move into the spotlight - AD HOC NEWS
Novartis AG stock (CH0012005267): US expansion push with new Texas radioligand site - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG stock (CH0012005267): Recent 1.93% gain on SIX Swiss Exchange - AD HOC NEWS
Novartis AG stock (CH0012005267): NewEdge Wealth boosts stake amid mixed analyst views - AD HOC NEWS
NVSNovartis AG ADR Stock Price and Quote - Finviz
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities - ChartMill
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report - Sahm
Sandoz, Novartis Must Face Generics Claims From GM, Others - Law360
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Sahm
Novartis AG Stock (CH0012005267): Q1 Revenue Miss Triggers Decline - AD HOC NEWS
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - ChartMill
Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates - Sahm
노바티스 ADR (NVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
0.46%
자본화:
|
볼륨(24시간):